, suggesting markets were set for another seesaw day driven by uncertainty regarding the potential impact of the Omicron Covid-19 variant. :
Shares of Vir Biotechnology jumped almost 10% premarket after a Covid-19 antibody treatment developed by it and GlaxoSmithKline was effective against the Omicron variant in early laboratory studies, the companies said, setting it apart from similar therapies that appear to work less well against the highly mutated strain.
, including its latest one, and that management has concluded there was a material weakness in its internal control.that the company told suppliers that demand for the iPhone 13 lineup has weakened.
do ESG revolution! do ESG blockchain revolution!
Россия Последние новости, Россия Последние новости
Similar News:Вы также можете прочитать подобные новости, которые мы собрали из других источников новостей
Источник: Reuters - 🏆 2. / 97 Прочитайте больше »
Источник: Forbes - 🏆 394. / 53 Прочитайте больше »
Источник: trtworld - 🏆 101. / 63 Прочитайте больше »